IAVI International AIDS Vaccine Initiative [to 22 August 2015]
http://www.iavi.org/press-releases/2015

.
:: IAVI Names Dr. Mark Feinberg New President and CEO
August 12, 2015
NEW YORK – The Board of Directors of the International AIDS Vaccine Initiative (IAVI) announced today that Mark Feinberg, MD, PhD, has been appointed IAVI’s new President and CEO, effective 8 September 2015.

“Mark brings a wealth of relevant experience and the passion to lead IAVI through the next chapter of our journey towards an AIDS vaccine,” said Alex Coutinho, IAVI Board Chair. “He shares IAVI’s strong commitment to program excellence, collaboration and partnership, responsible donor stewardship, and transparency.”

Feinberg has been actively involved in basic, translational and clinical HIV research efforts for more than 30 years. He brings broad and integrative perspectives from his leadership experiences in academia, government and industry; his familiarity with successful approaches for product development and delivery, and his track record for collaboration and innovation in forging new multi-sector partnership models. He has extensive experience advancing scientific and public health policy initiatives that focus on the prevention and treatment of HIV infection and other infectious diseases in resource-limited settings and that champion equitable and accelerated global access to innovative drugs and vaccines.

“I have directly witnessed the devastating impact that AIDS has had on individuals, families, communities and countries around the world, especially for the most vulnerable populations,” said Feinberg. “I am honored to have the opportunity to work with the IAVI team and their tremendous partners to fulfill IAVI’s promise to be the most effective partner, catalyst and facilitator in supporting collective efforts to accelerate the development of an effective HIV vaccine. This goal remains a critically important one, and achieving it will require all of us to apply the best science and creativity along with a high level of openness to forging new models of collaboration.”

For the past 11 years, Feinberg has served in leadership roles for the vaccine and infectious disease portfolios at Merck & Co., Inc., most recently as Chief Public Health and Science Officer for Merck Vaccines…